Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - AccuredRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

SAB Biotherapeutics (SABS) Long-Term Investments (2021 - 2025)

SAB Biotherapeutics (SABS) has disclosed Long-Term Investments for 3 consecutive years, with $46.9 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Long-Term Investments changed N/A year-over-year to $46.9 million, compared with a TTM value of $46.9 million through Dec 2025, changed N/A, and an annual FY2025 reading of $46.9 million, changed N/A over the prior year.
  • Long-Term Investments was $46.9 million for Q4 2025 at SAB Biotherapeutics, down from $50.6 million in the prior quarter.
  • Across five years, Long-Term Investments topped out at $116.2 million in Q3 2021 and bottomed at $1.2 million in Q1 2024.
  • Average Long-Term Investments over 3 years is $74.5 million, with a median of $83.4 million recorded in 2021.